On November 29, 2008, more than 20 well-known domestic experts including Wu Mengchao, an academician of the Chinese Academy of Sciences, gathered in Shanghai to participate in the special study on prevention of postoperative metastasis and recurrence of Likatin in the National Special Infectious Disease Prevention and Control Project. Experts believe that this research will likely significantly prolong the progression-free survival of liver cancer surgery and significantly improve the survival rate of liver cancer.
Primary liver cancer is the second largest tumor in China. The high recurrence rate after surgery has not improved the survival rate of liver cancer patients. How to control the recurrence and metastasis of liver cancer is the key to improve the overall surgical outcome of liver cancer.
Since 1982, after a long-term study by the Cell Engineering Center of the Fourth Military Medical University headed by Chen Zhinan, an academician of the Chinese Academy of Engineering, it has been found that rituximab in iodine [131I] rituximab injection (licartin) can be highly Selectively reaching the liver cancer site, the iodine [131I] carried by it can specifically kill liver cancer cells. The clinical experimental data showed that the clinical response rate reached 86.30%.
Another trial of liver cancer patients using liver cancer after resection to prevent recurrence showed that the relapse rate was significantly reduced by 30.4% and the survival rate was increased by 20.6% in the treatment group compared with the control group. Alpha-fetoprotein remained at normal levels for a longer period of time and no drug-related toxicity was observed.
According to reports, multi-center, large-sample liver cancer surgery Likatin interventional anti-relapse treatment clinical study will follow.
Primary liver cancer is the second largest tumor in China. The high recurrence rate after surgery has not improved the survival rate of liver cancer patients. How to control the recurrence and metastasis of liver cancer is the key to improve the overall surgical outcome of liver cancer.
Since 1982, after a long-term study by the Cell Engineering Center of the Fourth Military Medical University headed by Chen Zhinan, an academician of the Chinese Academy of Engineering, it has been found that rituximab in iodine [131I] rituximab injection (licartin) can be highly Selectively reaching the liver cancer site, the iodine [131I] carried by it can specifically kill liver cancer cells. The clinical experimental data showed that the clinical response rate reached 86.30%.
Another trial of liver cancer patients using liver cancer after resection to prevent recurrence showed that the relapse rate was significantly reduced by 30.4% and the survival rate was increased by 20.6% in the treatment group compared with the control group. Alpha-fetoprotein remained at normal levels for a longer period of time and no drug-related toxicity was observed.
According to reports, multi-center, large-sample liver cancer surgery Likatin interventional anti-relapse treatment clinical study will follow.
Herbal Extracts For Sports Nutrition
Herbal Extracts For Sports Nutrition
Tribulus Terrestris Extract for Sexual Power,Epimedium Extract Icariin and Icariins,Grape Seed Extract with Polyphenol,High Quality Red Beet Root Powder Extract
Excellent Health Products Co.,Ltd. , https://www.sino-excellent.com